Pharma

Moderna and Merck’s personalised mRNA vaccine clears Phase 3 in melanoma

HQ Team August 20, 2026: Moderna’s stock more than doubled, surging as much as 177% intraday to $174.38 on Aug. 19, 2026, after.

Read More